GlaxoSmithKline Pakistan Limited (GSK Pakistan) has reported a solid financial performance for the six months ended June 30, 2026, with growth in revenue, operating profit and profit after taxation. The company has also announced an interim cash dividend of Rs. 7 per share, reflecting its continued focus on shareholder returns.
According to the financial results released following the Board of Directors’ meeting on August 25, 2026, GSK Pakistan generated revenue of Rs. 31.52 billion during the first half of 2026, compared with Rs. 30.30 billion in the corresponding period of 2025. This represents an increase of about 4 percent year-on-year.
The company’s profitability showed stronger improvement than its top-line growth. Gross profit rose to Rs. 11.92 billion from Rs. 10.70 billion a year earlier, while operating profit increased to Rs. 7.96 billion from Rs. 7.23 billion. The figures indicate that the company maintained healthy operating performance despite higher selling, marketing, distribution and administrative expenses.
Finance charges also declined considerably, falling to Rs. 29.5 million during the six-month period from Rs. 214.4 million in the same period last year. As a result, profit before income tax increased to Rs. 7.93 billion, compared with Rs. 7.02 billion in the first half of 2025.
After accounting for income tax of Rs. 3.35 billion, GSK Pakistan posted profit after taxation of Rs. 4.58 billion, up from Rs. 4.20 billion in the comparable period. Earnings per share consequently increased to Rs. 14.38 from Rs. 13.17.
Interim Dividend Announced
Alongside its financial results, the company announced an interim cash dividend of Rs. 7.00 per share, equivalent to 70 percent. No bonus shares, right shares or other corporate actions were announced with the results.
The company stated that shareholders whose names appear in the Register of Members on August 31, 2026, will be entitled to the dividend. The share transfer books are scheduled to remain closed from September 1 to September 3, 2026.
Stronger Financial Position
GSK Pakistan’s balance sheet also remained substantial at the end of June. Total assets stood at approximately Rs. 52.58 billion, compared with Rs. 50.68 billion at December 31, 2025. Total equity increased to Rs. 34.43 billion from Rs. 33.67 billion.
Cash and bank balances stood at Rs. 8.43 billion at June 30, 2026, compared with Rs. 8.59 billion at the end of December 2025. The company’s cash flow statement also showed net cash generated from operating activities of Rs. 3.88 billion during the first half of the year.
Positive First-Half Performance
Overall, GSK Pakistan’s first-half results point to continued financial strength. Revenue grew at a moderate pace, while improvements in gross profit, operating profit and lower finance charges helped the company deliver stronger bottom-line results.
With profit after taxation rising to Rs. 4.58 billion and earnings per share reaching Rs. 14.38, the company enters the second half of 2026 from a stronger earnings position. The Rs. 7 per share interim dividend further highlights the company’s commitment to providing returns to shareholders.
The financial results for the half year ended June 30, 2026, were submitted as part of the company’s reporting requirements, with the accompanying statements covering its financial position, changes in equity and cash flows.
